October 20th 2024
Sophia Humphreys, PharmD, explains that expanding biosimilars into new therapeutic areas faces hesitance due to maintenance therapies, emphasizing the importance of education, and highlights factors like formulation preferences, interchangeability, and payer coverage as key drivers of adalimumab biosimilar competition.